GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acurx Pharmaceuticals Inc (NAS:ACXP) » Definitions » 3-Year RORE %

Acurx Pharmaceuticals (Acurx Pharmaceuticals) 3-Year RORE % : -8.68% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Acurx Pharmaceuticals 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Acurx Pharmaceuticals's 3-Year RORE % for the quarter that ended in Mar. 2024 was -8.68%.

The industry rank for Acurx Pharmaceuticals's 3-Year RORE % or its related term are showing as below:

ACXP's 3-Year RORE % is ranked worse than
50.96% of 1403 companies
in the Biotechnology industry
Industry Median: -7.75 vs ACXP: -8.68

Acurx Pharmaceuticals 3-Year RORE % Historical Data

The historical data trend for Acurx Pharmaceuticals's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acurx Pharmaceuticals 3-Year RORE % Chart

Acurx Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
- - - 21.18 -6.94

Acurx Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.40 4.59 -7.33 -6.94 -8.68

Competitive Comparison of Acurx Pharmaceuticals's 3-Year RORE %

For the Biotechnology subindustry, Acurx Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acurx Pharmaceuticals's 3-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Acurx Pharmaceuticals's 3-Year RORE % falls into.



Acurx Pharmaceuticals 3-Year RORE % Calculation

Acurx Pharmaceuticals's 3-Year RORE % for the quarter that ended in Mar. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -1.18--1.51 )/( -3.8-0 )
=0.33/-3.8
=-8.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2024 and 3-year before.


Acurx Pharmaceuticals  (NAS:ACXP) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Acurx Pharmaceuticals 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Acurx Pharmaceuticals's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acurx Pharmaceuticals (Acurx Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
259 Liberty Avenue, Staten Island, NY, USA, 10305
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
Executives
David P Luci director, 10 percent owner, officer: President and CEO
Robert J Deluccia director, 10 percent owner 40 WASHINGTON STREET, SUITE 220, WELLESLEY HILLS MA 02481
Carl Sailer director 4 GREENBRIAR LANE, MONTVALE NJ 07645
Thomas L Harrison director
Joseph C Scodari director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Jack H Dean director C/O RESEARCH PHARMACEUTICAL SERVICES,INC, 520 VIRGINIA DRIVE, FORT WASHINGTON PA 19034
Robert G. Shawah officer: Chief Financial Officer C/O DIPEXIUM PHARMACEUTICALS, LLC, 74 BROAD STREET, NEW YORK NY 10004
James J. Donohue director C/O ACURX PHARMACEUTICALS, INC., 259 LIBERTY AVENUE, STATEN ISLAND NY 10305

Acurx Pharmaceuticals (Acurx Pharmaceuticals) Headlines